New COVID Therapeutic Development Hitting Regulatory Wall At US FDA

FDA trial design criteria pose challenges for new COVID therapeutic development, frustrating companies and NIH and prompting a tense meeting earlier this summer, according to audio obtained by the Pink Sheet.